Search results
Showing 1216 to 1230 of 1809 results for nice guidelines
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
Develop our recommendations on a NICE committee as a chair, professional member or person with lived experience.
How we collect and use your personal information, and your rights under data protection legislation
Evidence standards framework for digital health technologies (ECD7)
This document describes an evidence standards framework (ESF) for digital health technologies (DHTs). It was developed by NICE between June 2018 and February 2019 in collaboration with NHS England, Public Health England and MedCity. The work was commissioned by NHS England.
Show all sections
- Overview
- Introduction
- Section A: Technologies suitable for evaluation using the evidence standards framework
- Section B: Classification of digital health technologies
- Section C: Evidence standards tables
- Terms used in the evidence standards framework
- How to meet the standards
- Section D: Early deployment standards for evidence-generation programmes
The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)
NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers
have an important part to play in the treatment of schizophrenia. NICE clinical guideline 82 identified family intervention...
NICE has developed a medtech innovation briefing (MIB) on StoneChecker for kidney stone evaluation .
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (TA529)
Evidence-based recommendations on crizotinib (Xalkori) for treating ROS1-positive advanced non-small-cell lung cancer in adults.
U-Drain for people needing night drainage of urine or dialysis fluid (MIB95)
NICE has developed a medtech innovation briefing (MIB) on U-Drain for people needing night drainage of urine or dialysis fluid .
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
NICE has developed a medtech innovation briefing (MIB) on InterDry for intertrigo .